BACKGROUND The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to defibrillate ven-
registry (3) (4) (5) . These EFFORTLESS and IDE study patients were pooled for analysis of 889 patients (308 in the IDE trial, 568 in the EFFORTLESS registry, and 13 in both studies) followed for an average of 1.8 years and 1,571 patient-years (5) .
This paper provides the first report of the full EFFORTLESS cohort, which is the largest S-ICD database in the world with the longest follow-up so far. This includes nearly 1,000 patients followed for an average of 3.1 years (3,053 patient-years), enabling a comprehensive analysis of current important issues related to S-ICD performance. The primary goal of the EFFORTLESS registry is to demonstrate the safety of the S-ICD by evaluating complications and inappropriate shock rate (6) . In addition, the following important outcomes for device performance and appropriate therapy were analyzed: 1) burden and predictors of monomorphic ventricular tachycardia (MVT); 2) incidence of recurrent MVT and impact of lack of availability of antitachycardia pacing (ATP); 3) differences in performance of the S-ICD in converting induced versus spontaneous episodes; and 4) reasons for device explant.
METHODS
The EFFORTLESS S-ICD registry is an observational, nonrandomized, standard-of-care registry enrolling up to 1,000 patients at 42 clinical centers in 10 countries. Details of the study design and endpoints were reported previously (6) . 
RESULTS
Of 994 patients enrolled, 6 were withdrawn before the implantation procedure, 3 retrospective enrollments were withdrawn before data entry due to in- 
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A U G U S T 1 5 , 2 0 1 7 : 8 3 0 -4 1 implantation was the sole reason for admission, and 14 days when hospitalized for other reasons, of which 2 days were from implantation to discharge.
COMPLICATIONS. For the primary pre-specified safety endpoint, the 30-and 360-day S-ICD complication rates were 0.3% (95% confidence interval [CI]:
0% to 0.6%) and 2.0% (95% CI: 1.3% to 3.1%),
respectively. The most common S-ICD complications were cardiac oversensing, leading to inappropriate shocks (11 patients, 1.1%) and discomfort (n ¼ 8, 0.8%). Complications related to product performance occurred due to premature battery depletion (n ¼ 5), inability to communicate with the device (n ¼ 3), or programmer error code (n ¼ 1), with no reports of lead failure.
The overall complication rate was 4.1% at 30 days and 8.4% at 360 days ( Figure 2A ). All S-ICD system-or procedure-related complications are shown in Table 2 . A total of 115 (11.7%) patients experienced a showing the number of patients enrolled, receiving an implant, and remaining in follow-up at 30 days and at each annual follow-up through 5 years. The number of patients exiting the study for death or withdrawal at each interval is shown to the right, as well as the number of patients remaining in the study within the respective follow-up interval.
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Infections requiring device removal occurred in 24 (2.4%) patients over the 3.1-year average follow-up.
By Kaplan-Meier analysis, infections requiring device removal were most common in the first year ( Figure 2B ). The large EFFORTLESS database also provides more data on the efficacy of the S-ICD over time, during both induced and spontaneous arrhythmias.
ACUTE CONVERSION TEST RESULTS. Table 3 Table 2 ). Twenty-two (2.2%) patients had >1 MVT treated episode over the average 3.1-year follow-up. The 1-and 5-year Kaplan-Meier rates of appropriate shock were 5.8% and 13.5% (MVT 3.8% and 7.4%; PVT or VF 3.0% and 8.4%), respectively. patients, complication rates were equivalent, with higher rates of lead complications in the TV-ICD patients and more nonlead complications, such as erosion, in the S-ICD patients (9,10).
APPROPRIATE THERAPY. The study exclusion criteria mimic the device contraindications by excluding patients with a history of recurring VT who could benefit from ATP. This is likely to skew the demographics of this study in comparison with TV-ICD studies. The average age is younger than in TV-ICD studies, with a higher proportion of inherited diseases than would be expected in a TV-ICD study.
It is not surprising that secondary prevention patients and patients with prior cardiac arrest were more likely to receive appropriate therapy, whether for PVT or VF or MVT. Patients with ion channelopathy were less likely to receive therapy for MVT.
Renal disease was a significant predictor of therapy for PVT or VF, which was not seen in the IDE trial that excluded patients with renal disease. Serum creatinine 
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The complication risk is compared between patients with the characteristic present and those with the characteristic absent, or for each unit increase, as described in Table 1 .
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and renal dysfunction has been seen as an independent predictor of the time to first appropriate shock and sudden cardiac death in several TV-ICD studies outweighs the disadvantages in the many (19) . Such data will assist implanters to make an individual patient-based choice of the type of defibrillator.
High-rate programming to evaluate ATP need has been evaluated in TV-ICD studies. Clementy et al. (20) showed that programming shock-only therapy Figure 1) . In parallel to this change in implantation practice, the current longer-term multivariate analysis no longer identified dual-zone programming as lowering the rate of inappropriate therapy, whereas single-zone programming inappropriate therapy rates were lower than in previous studies (5) . Alternative explanations could be reprogramming after implantation, the types of patients programmed to a single zone, or that an analysis artifact due to a low number of patients programmed to a single zone could have influenced these findings. In view of the collective data of several S-ICD studies, dual-zone programming should remain the standard for all patients.
LESSONS LEARNED FROM CONVERSION TESTING.
As S-ICD technology is still novel, conversion testing during implantation is still recommended to ensure optimal sensing of induced VF and effective defibrillation (29) . In the EFFORTLESS registry, there were no cases of VF under-detection preventing shock delivery, and failed acute conversion testing occurred in only a limited number of patients (<1%). Repositioning of the electrode or generator to encompass the heart may be needed to achieve successful conversion. In patients with a high body mass index, both the electrode and the generator must be positioned under the fat, in direct contact with the fascia, to ensure optimal shock impedances. The EFFORTLESS S-ICD Study Midterm Results
